Skip to main content
. Author manuscript; available in PMC: 2023 Sep 14.
Published in final edited form as: Cell Host Microbe. 2022 Aug 17;30(9):1207–1218.e7. doi: 10.1016/j.chom.2022.07.013

Figure 4: Transcriptomic signature of ddCyCMV/SIV protection.

Figure 4:

(A) Principal component analysis bi-plot showing transcriptomic variation in the dataset. See also Figure S4. (B) Total number of differentially expressed genes at each vaccine phase time point (D1-D14 = days 1, 3, 7, and 14 post ddCyCMV/SIV prime, and BD0-BD14 = days 0, 1, 3, 7, and 14 post ddCyCMV/SIV boost) relative to baseline in SIV protected and unprotected MCM. (C) Time series heatmap of the 68–1 RhCMV/SIV protection signature genes enriched in ddCyCMV/SIV protected MCM. Plotted are log2 fold change values of the 122 leading edge genes across the vaccination time series in MCM (left) and RM (right), with RM whole blood one day post exogenous IL-15 treatment in the middle. RM data are from Barrenas et al. (D) Pre-vaccination baseline normalized expression Z-score boxplots of the 84 up-regulated leading-edge genes identified in panel C distinguishes SIV protection outcome (top plot). Pre-vaccination baseline normalized expression Z-score boxplots of the 38 down-regulated leading edge genes identified in panel C distinguishes outcome (bottom plot). See also Figure S5.